esketamine has been researched along with Suicidal Ideation in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (4.76) | 24.3611 |
| 2020's | 20 (95.24) | 2.80 |
| Authors | Studies |
|---|---|
| Nikayin, S; Sanacora, G | 1 |
| Aguiar, PM; Lima, TM; Visacri, MB | 1 |
| Kasper, S; Lanzenberger, R; Naderi-Heiden, A; Praschak-Rieder, N; Unterholzner, J; Vanicek, T | 1 |
| Joshi, K; Le, HH; Li, S; Sheehan, JJ; Toro-Diaz, H; Voelker, J | 1 |
| Courtet, P; Lengvenyte, A; Olié, E; Strumila, R | 1 |
| Alves-Pereira, R; Bandeira, ID; Cardoso, TA; Faria-Guimarães, D; Fontes, M; Kapczinski, F; Lacerda, ALT; Leal, GC; Mello, RP; Quarantini, LC; Sampaio, AS; Silva, SS; Souza, LS; Souza-Marques, B; Vieira, F | 1 |
| Chao, Z; Fu, L; Hu, Z; Lan, X; Li, W; Liu, H; Ning, Y; Wang, C; Ye, Y; Zhang, F; Zhou, Y | 1 |
| Bernardo, WM; Floriano, I; Silvinato, A | 1 |
| Canuso, CM; Fu, DJ; Ionescu, DF; Jamieson, C; Lane, R; Molero, P; Qiu, X; Rozjabek, H | 1 |
| Anjo, J; Borentain, S; Canuso, CM; Fu, DJ; Guo, S; Mathews, M; Nash, AI; O'Hara, M; Shi, L; Zhang, Q | 1 |
| Fu, DJ; Hong, JP; Ju, PC; Li, CT; Madriaga, G; Malek, AZA; Paik, JW; Siggins, S; Sulaiman, AH; Zhuo, J | 1 |
| Corlett, PR; Hershenberg, R; Joormann, J; Kitay, BM; Macaluso, M; Martinez-Kaigi, V; Murphy, E; Nikayin, S; Rhee, TG; Sanacora, G; Shelton, RC; Thase, ME; Wilkinson, ST | 1 |
| Bartoli, F; Wlkinson, ST | 1 |
| Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Lane, R; Li, X; Lim, P; Manji, H; Sanacora, G | 1 |
| Canuso, CM; Drevets, WC; Fu, DJ; Hough, D; Ionescu, DF; Kasper, S; Lane, R; Lim, P; Manji, H; Qiu, X | 1 |
| Courtet, P; Nobile, B; Olié, E | 1 |
| Carvalho, I; Chen-Li, D; Gill, H; Lee, Y; Lipsitz, O; Lui, LMW; Mansur, RB; McIntyre, RS; Narsi, F; Rodrigues, NB; Rosenblat, JD; Xiong, J | 1 |
| Berk, M; Brietzke, E; Dodd, S; Gorwood, P; Ho, R; Iosifescu, DV; Kasper, S; Kratiuk, K; Lee, JG; Lee, Y; Lopez Jaramillo, C; Lui, LMW; Mansur, RB; McIntyre, RS; Murrough, JW; Nemeroff, CB; Papakostas, GI; Rosenblat, JD; Sanacora, G; Stahl, S; Subramaniapillai, M; Thase, M; Vieta, E; Young, AH; Zarate, CA | 1 |
| Brietzke, E; Di Vincenzo, JD; Gill, H; Ho, R; Lui, LMW; McIntyre, RS; Ng, J; Rodrigues, NB; Rosenblat, JD; Siegel, AN; Teopiz, KM | 1 |
| Fonseca-Perezamador, A; García-Mendoza, AM; Kobayashi-Romero, LF; Lamas-Aguilar, RM; Pérez-Esparza, R | 1 |
8 review(s) available for esketamine and Suicidal Ideation
| Article | Year |
|---|---|
Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Disease Management; Humans; Ketamine; Risk Assessment; Suicidal Ideation | 2021 |
Use of ketamine and esketamine for depression: an overview of systematic reviews with meta-analyses.
Topics: Antidepressive Agents; Depressive Disorder; Humans; Ketamine; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Suicidal Ideation; Systematic Reviews as Topic | 2022 |
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
The use of esketamine in the treatment of patients with severe depression and suicidal ideation: systematic review and meta-analysis.
Topics: Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2023 |
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Topics: Adult; Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Patient Reported Outcome Measures; Quality of Life; Randomized Controlled Trials as Topic; Suicidal Ideation | 2023 |
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis.
Topics: Bipolar Disorder; Depression; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2021 |
Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
Topics: Antidepressive Agents; Delivery of Health Care; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dissociative Disorders; Excitatory Amino Acid Antagonists; Humans; Hypertension; Implementation Science; Ketamine; Lower Urinary Tract Symptoms; Monitoring, Physiologic; Patient Selection; Personnel Staffing and Scheduling; Psychoses, Substance-Induced; Substance-Related Disorders; Suicidal Ideation | 2021 |
Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Retrospective Studies; Suicidal Ideation; Suicide | 2021 |
5 trial(s) available for esketamine and Suicidal Ideation
| Article | Year |
|---|---|
The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial.
Topics: Depressive Disorder, Major; Humans; Ketamine; Randomized Controlled Trials as Topic; Suicidal Ideation; Suicide | 2022 |
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Humans; Suicidal Ideation; Suicide; Treatment Outcome | 2023 |
Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.
Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Humans; Randomized Controlled Trials as Topic; Suicidal Ideation | 2023 |
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Suicidal Ideation; Young Adult | 2020 |
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Topics: Administration, Intranasal; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Ketamine; Male; Middle Aged; Nasal Sprays; Outcome Assessment, Health Care; Patient Acuity; Suicidal Ideation; Young Adult | 2021 |
8 other study(ies) available for esketamine and Suicidal Ideation
| Article | Year |
|---|---|
Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder.
Topics: Antidepressive Agents; Borderline Personality Disorder; Depression; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Impulsive Behavior; Ketamine; Suicidal Ideation | 2022 |
US budget impact analysis of esketamine nasal spray in major depressive disorder with acute suicidal ideation/behavior.
Topics: Administration, Intranasal; Adult; Depressive Disorder, Major; Health Care Costs; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2022 |
Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Humans; Ketamine; Suicidal Ideation | 2022 |
Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placeb
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Humans; Nasal Sprays; Standard of Care; Suicidal Ideation; Treatment Outcome | 2023 |
Ketamine and esketamine for suicidal ideation: Recent progress and practical issues.
Topics: Adult; Depressive Disorder, Major; Humans; Ketamine; Psychiatric Status Rating Scales; Suicidal Ideation | 2020 |
A new indication for esketamine nasal spray (Spravato).
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2020 |
The Antisuicidal Effect of Esketamine Should Be Further Investigated.
Topics: Depressive Disorder, Major; Double-Blind Method; Humans; Ketamine; Nasal Sprays; Suicidal Ideation | 2020 |
Promises and concerns regarding the use of ketamine and esketamine in the treatment of depression.
Topics: Administration, Intranasal; Anesthetics, Dissociative; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Receptors, N-Methyl-D-Aspartate; Risk Factors; Substance-Related Disorders; Suicidal Ideation; United States; United States Food and Drug Administration | 2019 |